Axillary Management and Sentinel Node Biopsy for Surgeons — B-32 Staging, Z0011 and IBCSG Omission, AMAROS Radiotherapy Swap, SOUND Observation and Post-Neoadjuvant Targeted Dissection

The one-line answer

Axillary staging starts with sentinel biopsy in the clinically node-negative axilla and stops there when nodes are negative; limited sentinel positivity in breast-conserved disease treated with irradiation and systemic therapy needs no completion dissection; micrometastatic disease needs no dissection; radiotherapy replaces dissection with less lymphoedema where axillary treatment is indicated; ultrasound-negative small cancers can skip even sentinel surgery when pathology would not change adjuvant therapy; and node-positive disease downstaged by chemotherapy needs clipped-node targeted assessment because sentinel surgery alone after chemotherapy misses too much. The surgeon's error is never missing rarity; it is dissecting the Z0011-eligible axilla, ignoring the clipped node after chemotherapy, and staging the SOUND-eligible axilla that needed no surgery.^{[1][5][8][11]}

A 55-year-old woman with a 1.6 cm cancer, no palpable nodes and one positive sentinel node walks the whole topic in one patient: confirm she meets the lumpectomy-plus-irradiation fence before omitting dissection, quote the 10-year survival and recurrence numbers, offer radiotherapy instead of surgery where indicated, and keep clipped-node logic ready only if she had presented node-positive and received chemotherapy first.^[5][10][12]

Sentinel standard — staging with less morbidity

• To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer was the explicit ASCO purpose — staging, not therapy, is what the sentinel operation buys.^[1]
• SNB is an appropriate initial alternative to routine staging ALND for patients with early-stage breast cancer with clinically negative axillary nodes — the node-negative axilla is staged, not cleared.^[1]
• Appropriately identified patients with negative results of SNB, when done under the direction of an experienced surgeon, need not have completion ALND — negative sentinel surgery ends the axillary operation.^[1]
• Isolated cancer cells detected by pathologic examination of the SLN with use of specialized techniques are currently of unknown clinical significance — do not escalate the axilla on isolated cells alone.^[1]
• Data suggest that SNB is associated with less morbidity than ALND, but the comparative effects of these two approaches on tumor recurrence or patient survival are unknown was the honest 2005 caveat — the later randomised trials below answer the survival half.^[1]
• Sentinel lymph node biopsy (SLNB), the current gold standard for axillary staging for many breast cancer patients, has replaced axillary lymph node dissection (ALND) for clinically node-negative patients due to lower surgical morbidity while maintaining oncologic safety.^[17]
• Early randomized trials including the NSABP B-32 and ALMANAC trials established SLNB as a safe alternative to ALND for clinically node-negative patients with comparable overall survival (OS), disease-free survival (DFS), and regional control while significantly reducing complications such as lymphedema.^[17]

B-32 technique — identification, accuracy and the false-negative levers

• 5611 women with invasive breast cancer were randomly assigned to receive either SLN resection followed by immediate conventional ALND (n=2807; group 1) or SLN resection without ALND if SLNs were negative on intraoperative cytology and histological examination (n=2804; group 2) in the B-32 trial.^[2]
• SLNs were successfully removed in 97.2% of patients (5379 of 5536) in both groups combined — failure to find a sentinel node mandates dissection in the trial logic.^[2]
• The overall accuracy of SLN resection in patients in group 1 was 97.1% (2544 of 2619; 95% CI 96.4-97.7), with a false-negative rate of 9.8% (75 of 766; 95% CI 7.8-12.2).^[2]
• 65.1% (8571 of 13 171) of SLN specimens were both radioactive and blue — dual mapping dominates the identified packet.^[2]
• Allergic reactions related to blue dye occurred in 0.7% (37 of 5588) of patients with data on toxic effects — consent the blue dye as well as the axilla.^[2]
• Removal of more than one SLN and avoidance of excisional biopsy are important variables in reducing the false-negative rate — take more than one node and do not core the staging with an excisional biopsy cavity.^[2]

B-32 morbidity — why sentinel surgery won even before survival matured

• Three year post-surgical morbidity levels were compared between patients with negative sentinel lymph node dissection alone (SLND) and those with negative sentinel node dissection and negative axillary lymph node dissection (ALND) in the NSABP B-32 trial.^[3]
• Shoulder abduction deficits >or=10% peaked at 1 week for the ALND (75%) and SLND (41%) groups.^[3]
• Arm volume differences >or=10% at 36 months were evident for the ALND (14%) and SLND (8%) groups.^[3]
• Numbness and tingling peaked at 6 months for the ALND (49%, 23%) and SLND (15%, 10%) groups.^[3]
• The results of the NSABP B-32 study indicate the superiority of the SLND compared to the ALND treatment approach relative to post-surgical morbidity outcomes over a 3-year follow-up period.^[3]

Z0011 — 1-2 positive nodes without completion dissection

• Patients were women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to 2 SLNs containing metastases identified by frozen section, touch preparation, or hematoxylin-eosin staining on permanent section.^[4]
• All patients underwent lumpectomy and tangential whole-breast irradiation — Z0011 is a breast-conservation plus irradiation result, not a mastectomy rule.^[4]
• The median number of nodes removed was 17 with ALND and 2 with SLND alone — the trial compares a clearance against a sampling.^[4]
• At a median follow-up of 6.3 years (last follow-up, March 4, 2010), 5-year overall survival was 91.8% (95% confidence interval [CI], 89.1%-94.5%) with ALND and 92.5% (95% CI, 90.0%-95.1%) with SLND alone.^[4]
• Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival.^[4]
• Eligible patients were women with clinical T1 or T2 invasive breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases — memorise the fence before quoting the outcome.^[5]
• All patients had planned lumpectomy, planned tangential whole-breast irradiation, and adjuvant systemic therapy — with third-field radiation prohibited, so the axilla was not secretly irradiated into equivalence.^[5]
• At a median follow-up of 9.3 years (interquartile range, 6.93-10.34 years), the 10-year overall survival was 86.3% in the SLND alone group and 83.6% in the ALND group (HR, 0.85 [1-sided 95% CI, 0-1.16]; noninferiority P = .02).^[5]
• The 10-year disease-free survival was 80.2% in the SLND alone group and 78.2% in the ALND group (HR, 0.85 [95% CI, 0.62-1.17]; P = .32).^[5]
• These findings do not support routine use of axillary lymph node dissection in this patient population based on 10-year outcomes.^[5]

Z0011 regional control — the residual-disease paradox

• Four hundred forty-six patients were randomized to SLND alone and 445 to SLND and ALND — the long-term recurrence analysis keeps the original randomisation.^[6]
• Patients randomized to ALND had a median of 17 axillary nodes removed compared with a median of only 2 SLNs removed with SLND alone (P < 0.001).^[6]
• The cumulative incidence of nodal recurrences at 10 years was 0.5% in the ALND arm and 1.5% in the SLND alone arm (P = 0.28).^[6]
• Ten-year cumulative locoregional recurrence was 6.2% with ALND and 5.3% with SLND alone (P = 0.36).^[6]
• Despite the potential for residual axillary disease after SLND, SLND without ALND offers excellent regional control for selected patients with early metastatic breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.^[6]

Micrometastases — IBCSG 23-01 sets the 2 mm line

• We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm.^[7]
• Patients were eligible if they had clinically non-palpable axillary lymph node(s) and a primary tumour of 5 cm or less and who, after sentinel-node biopsy, had one or more micrometastatic (≤2 mm) sentinel lymph nodes with no extracapsular extension.^[7]
• 5-year disease-free survival was 87·8% (95% CI 84·4-91·2) in the group without axillary dissection and 84·4% (80·7-88·1) in the group with axillary dissection (log-rank p=0·16; HR for no axillary dissection vs axillary dissection was 0·78, 95% CI 0·55-1·11, non-inferiority p=0·0042).^[7]
• Axillary dissection could be avoided in patients with early breast cancer and limited sentinel-node involvement, thus eliminating complications of axillary surgery with no adverse effect on survival.^[7]
• Disease-free survival at 10 years was 76·8% (95% CI 72·5-81·0) in the no axillary dissection group, compared with 74·9% (70·5-79·3) in the axillary dissection group (HR 0·85, 95% CI 0·65-1·11; log-rank p=0·24; p=0·0024 for non-inferiority).^[8]
• Long-term surgical complications included lymphoedema of any grade in 16 (4%) of 453 patients in the no axillary dissection group and 60 (13%) of 447 in the axillary dissection group.^[8]
• The findings of the IBCSG 23-01 trial after a median follow-up of 9·7 years (IQR 7·8-12·7) corroborate those obtained at 5 years and are consistent with those of the 10-year follow-up analysis of the Z0011 trial.^[8]
• Together, these findings support the current practice of not doing an axillary dissection when the tumour burden in the sentinel nodes is minimal or moderate in patients with early breast cancer.^[8]
• Micrometastasis-focused trials (IBCSG 23-01, AATRM) showed that omission of ALND in patients with one or more micrometastases (≤ 2 mm) did not compromise survival or locoregional control.^[18]

AMAROS — radiotherapy instead of dissection where treatment is indicated

• If treatment of the axilla is indicated in patients with breast cancer who have a positive sentinel node, axillary lymph node dissection is the present standard was the pre-AMAROS baseline — the trial tests the swap, not the need.^[9]
• In the axillary lymph node dissection group, 220 (33%) of 672 patients who underwent axillary lymph node dissection had additional positive nodes — one third carry more disease than the sentinel sample shows.^[9]
• 5-year axillary recurrence was 0·43% (95% CI 0·00-0·92) after axillary lymph node dissection versus 1·19% (0·31-2·08) after axillary radiotherapy.^[9]
• Lymphoedema in the ipsilateral arm was noted significantly more often after axillary lymph node dissection than after axillary radiotherapy at 1 year, 3 years, and 5 years.^[9]
• Axillary lymph node dissection and axillary radiotherapy after a positive sentinel node provide excellent and comparable axillary control for patients with T1-2 primary breast cancer and no palpable lymphadenopathy.^[9]
• In this open-label multicenter phase III noninferiority trial, 4,806 patients underwent SN biopsy; 1,425 were node-positive and randomly assigned to either ALND (n = 744) or ART (n = 681).^[10]
• Per intention-to-treat analysis, 10-year ARR cumulative incidence was 0.93% (95% CI, 0.18 to 1.68; seven events) after ALND and 1.82% (95% CI, 0.74 to 2.94; 11 events) after ART (hazard ratio [HR], 1.71; 95% CI, 0.67 to 4.39).^[10]
• There were no differences in OS (HR, 1.17; 95% CI, 0.89 to 1.52) or DFS (HR, 1.19; 95% CI, 0.97 to 1.46).^[10]
• ALND was associated with a higher lymphedema rate in updated 5-year analyses (24.5% v 11.9%; P < .001).^[10]
• Considering less arm morbidity, ART is preferred over ALND for patients with SN-positive cT1-2 breast cancer.^[10]
• Mixed-burden trials (ACOSOG Z0011, AMAROS) included patients with 1-2 positive sentinel lymph nodes, regardless of micrometastatic or macrometastatic size, and confirmed the safety of avoiding ALND when appropriate systemic therapy and radiotherapy are given.^[18]
• Subsequent trials including ACOSOG Z0011, IBCSG 23-01, and AMAROS further supported omission of completion ALND (cALND) for selected patients with limited SLN metastases.^[17]

SOUND — omitting even the sentinel biopsy in small ultrasound-negative cancers

• Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node staging of patients with early breast cancer (BC), but its necessity can be questioned since surgery for examination of axillary nodes is not performed with curative intent.^[11]
• A total of 1463 women of any age with BC up to 2 cm and a negative preoperative axillary ultrasonography result were enrolled and randomized between February 6, 2012, and June 30, 2017.^[11]
• In the SLNB group, 97 patients (13.7%) had positive axillary nodes — ultrasound negativity misses roughly one in seven.^[11]
• Five-year distant DDFS was 97.7% in the SLNB group and 98.0% in the no axillary surgery group (log-rank P = .67; hazard ratio, 0.84; 90% CI, 0.45-1.54; noninferiority P = .02).^[11]
• Omission of axillary surgery was noninferior to SLNB in patients with small BC and a negative result on ultrasonography of the axillary lymph nodes.^[11]
• Patients with these features can be safely spared any axillary surgery whenever the lack of pathological information does not affect the postoperative treatment plan — the SOUND caveat that fails the viva when forgotten.^[11]
• SOUND and INSEMA established non-inferiority of observation vs. SLNB in clinically node-negative (cN0), imaging-negative tumors.^[18]

Neoadjuvant accuracy — SENTINA timing and Z1071 false negatives

• Of 1737 patients who received treatment, 1022 women underwent sentinel-lymph-node biopsy before neoadjuvant chemotherapy (arms A and B), with a detection rate of 99.1% (95% CI 98.3-99.6; 1013 of 1022).^[13]
• In patients who converted after neoadjuvant chemotherapy from cN+ to ycN0 (arm C), the detection rate was 80.1% (95% CI 76.6-83.2; 474 of 592) and false-negative rate was 14.2% (95% CI 9.9-19.4; 32 of 226).^[13]
• The false-negative rate was 24.3% (17 of 70) for women who had one node removed and 18.5% (10 of 54) for those who had two sentinel nodes removed (arm C).^[13]
• Sentinel-lymph-node biopsy is a reliable diagnostic method before neoadjuvant chemotherapy.^[13]
• After systemic treatment or early sentinel-lymph-node biopsy, the procedure has a lower detection rate and a higher false-negative rate compared with sentinel-lymph-node biopsy done before neoadjuvant chemotherapy.^[13]
• The American College of Surgeons Oncology Group Z1071 trial reported a false-negative rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer.^[12]
• Z1071 was a multi-institutional trial wherein women with clinical T0-T4,N1-N2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadjuvant chemotherapy.^[12]
• In the neoadjuvant setting, studies such as ACOSOG Z1071, SENTINA, and SN-FNAC evaluated SLNB accuracy after NAC and informed the development of optimized techniques, including dual-tracer mapping and TAD, to reduce false-negative rates.^[17]

Clipped node rescue — from Z1071 clip to targeted dissection

• In 107 (75.9%) patients where the clipped node was within the SLN specimen, the FNR was 6.8% (confidence interval [CI]: 1.9%-16.5%).^[12]
• In 34 (24.1%) cases where the clipped node was in the ALND specimen, the FNR was 19.0% (CI: 5.4%-41.9%).^[12]
• Clip placement at diagnosis of node-positive disease with removal of the clipped node during SLN surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy.^[12]
• Placing clips in nodes with biopsy-confirmed metastasis before initiating neoadjuvant therapy allows for evaluation of response in breast cancer.^[14]
• Of 208 patients enrolled in this study, 191 underwent ALND, with residual disease identified in 120 (63%).^[14]
• In patients undergoing SLND and ALND (n = 118), the FNR was 10.1% (95% CI, 4.2 to 19.8), which included seven false-negative events in 69 patients with residual disease.^[14]
• Adding evaluation of the clipped node reduced the FNR to 1.4% (95% CI, 0.03 to 7.3; P = .03).^[14]
• The clipped node was not retrieved as an SLN in 23% (31 of 134) of patients, including six with negative SLNs but metastasis in the clipped node.^[14]
• TAD followed by ALND was performed in 85 patients, with an FNR of 2.0% (1 of 50; 95% CI, 0.05 to 10.7).^[14]
• Marking nodes with biopsy-confirmed metastatic disease allows for selective removal and improves pathologic evaluation for residual nodal disease after chemotherapy.^[14]

Post-neoadjuvant triage — ultrasound response and safe omission after downstaging

• Axillary US images obtained after neoadjuvant chemotherapy and surgical pathologic findings were available for 611 patients.^[16]
• Residual nodal disease was present in 373 patients (61.0%), and 238 (39.0%) had a complete nodal pathologic response.^[16]
• Increased cortical thickness (mean, 3.5 mm for node-positive disease vs 2.5 mm for node-negative disease) was associated with residual nodal disease.^[16]
• Patients with nodal morphologic type I or II had the lowest rate of residual nodal disease (51 of 91 patients [56.0%] and 138 of 246 patients (56.1%), respectively), whereas those with nodal morphologic type VI had the highest rate (44 of 55 patients [80.0%]) (p = 0.004).^[16]
• Axillary US performed after neoadjuvant chemotherapy is useful for nodal response assessment, with longer short-axis diameter, longer long-axis diameter, increased cortical thickness, and absence of fatty hilum significantly associated with residual nodal disease after neoadjuvant chemotherapy.^[16]
• In this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020.^[15]
• The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization).^[15]
• The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively.^[15]
• The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55).^[15]
• The results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB.^[15]
• Axillary surgery should be optimized to disease biology, systemic therapy response, and patient quality of life.^[18]

Follow-up and exam traps

• Upfront follow-up is fence-checked: T1-T2 nonpalpable disease with 1-2 positive sentinels treated by lumpectomy, tangential irradiation and systemic therapy needs no completion dissection, with 10-year survival 86.3% vs 83.6% and nodal recurrence 0.5% vs 1.5% as the consent numbers.^[5][6]
• Micrometastatic follow-up trades lymphoedema for reassurance: omit dissection for 2 mm-or-smaller sentinel disease without extracapsular extension, quoting 10-year disease-free survival 76.8% vs 74.9% with 4% vs 13% lymphoedema.^[8]
• Indicated-axilla follow-up offers the swap: where treatment is required for cT1-2 sentinel-positive disease, radiotherapy and dissection give 10-year recurrence 1.82% vs 0.93% with no survival difference, so choose radiotherapy for 11.9% vs 24.5% lymphoedema.^[10]
• Small-cancer follow-up respects the SOUND caveat: tumours up to 2 cm with negative ultrasound can skip sentinel surgery with 97.7% vs 98.0% distant control, but only when missing pathology leaves adjuvant decisions unchanged despite 13.7% occult positivity.^[11]
• Post-chemotherapy follow-up is clip-led: expect 61.0% residual disease after chemotherapy in initially node-positive patients, retrieve the clipped node with localisation, remove more than one sentinel node, and interpret cortical thickening and hilum loss as residual-disease signals — because sentinel-alone false negatives of 12.6-14.2% fall to 1.4-2.0% only with the clipped node in the specimen.^[12][14][16]

References18ShowHide

1. [1]Lyman GH, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol, 2005.PMID 16157938
2. [2]Krag DN, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol, 2007.PMID 17851130
3. [3]Ashikaga T, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol, 2010.PMID 20648579
4. [4]Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 2011.PMID 21304082
5. [5]Giuliano AE, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA, 2017.PMID 28898379
6. [6]Giuliano AE, et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg, 2016.PMID 27513155
7. [7]Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol, 2013.PMID 23491275
8. [8]Galimberti V, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol, 2018.PMID 30196031
9. [9]Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol, 2014.PMID 25439688
10. [10]Bartels SAL, et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol, 2023.PMID 36383926
11. [11]Gentilini OD, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol, 2023.PMID 37733364
12. [12]Boughey JC, et al. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg, 2016.PMID 26649589
13. [13]Kuehn T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol, 2013.PMID 23683750
14. [14]Caudle AS, et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol, 2016.PMID 26811528
15. [15]Montagna G, et al. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. JAMA Oncol, 2024.PMID 38662396
16. [16]Le-Petross HT, et al. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol, 2018.PMID 29381381
17. [17]Stanczyk M, et al. The Past, Present, and Future of Sentinel Lymph Node Biopsy in Breast Cancer. Ann Surg Oncol, 2026.PMID 42213262
18. [18]Park WK, et al. Axillary Surgery in Breast Cancer: Evidence-Based De-escalation Across Upfront and Post-Neoadjuvant Settings. J Breast Cancer, 2026.PMID 41612659